๐Ÿ”ฌDeep Research

DNA โ€” Ginkgo Bioworks ยท catalysts, narrative & risks

ยท20 sourcesDNA forecast โ†’

Ginkgo Bioworks (NYSE: DNA) โ€” As of October 25, 2026

Below is a point-in-time research summary. It is informational only, not investment advice.

Company snapshot (Oct 23, 2026)

  • NYSE-listed biotech developing a cell-engineering platform [16], [18].
  • Price ~$9.99, market cap ~$672.7M, ~67.34M shares outstanding, beta 1.79 [20].
  • 52-week range $5.37โ€“$18.22 [20]. Over the trailing 12 months DNA fell roughly 26% while the S&P 500 rose ~12% [18].
  • Fundamentals are weak relative to peers: trailing revenue ~$132.4M (โˆ’37%) and net loss ~$290.8M, EPS โˆ’$4.96 [20]. For context, 2025 revenue was $170.2M, down 25% [20]. (Note [1] cites "$170M revenue," which appears to reflect the 2025 annual figure rather than the trailing-twelve-month number.)

AI-assisted research from the K3vl4r desk โ€” not personalized investment advice. More research โ†’